Wednesday, 23 September 2026European Markets

BOIRON And 2 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - abn amro bank n.v. (abn.as), boiron (boi.pa), home invest be. (homi.br) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio at the moment. the payout ratio in itself isn't a promise of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

when investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. abn amro bank n.v. (abn.as)

47.45% payout ratio

abn amro bank n.v. provides various banking products and services to retail, private, and business clients in the netherlands and internationally. it operates through three segments: personal & business banking, wealth management, and corporate banking. the company provides savings and deposits products; labelled residential mortgage products under the florius brands; and consumer loans under the alpha credit nederland, credivance, defam, moneyou, and abn amro brands. it also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. in addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. abn amro bank n.v. was incorporated in 2009 and is headquartered in amsterdam, the netherlands.

earnings per share

as for profitability, abn amro bank n.v. has a trailing twelve months eps of €1.96.

pe ratio

abn amro bank n.v. has a trailing twelve months price to earnings ratio of 7.75. meaning, the purchaser of the share is investing €7.75 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.34%.

revenue growth

year-on-year quarterly revenue growth declined by 15.2%, now sitting on 7.8b for the twelve trailing months.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on apr 21, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 10.41%.

more news about abn amro bank n.v..

2. boiron (boi.pa)

32.87% payout ratio

boiron sa manufactures and sells homeopathic medicines in france, rest of europe, north america, and internationally. the company offers non-proprietary, proprietary, branded homeopathic medicines. its branded homeopathic medicines include oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; stodal and stodaline for treating coughs; arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; camilia for the treatment of teething problems for babies; and sédatif pc to treat anxiety and emotional, and minor sleep disorders. the company's homeopathic medicines also comprise coryzalia for the treatment of cold symptoms and rhinitis; homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and homéovox for vocal disorders. in addition, it provides dietary supplement; dermoplasmine stick, baume, and mousse to treat dry lips and skin; mag' nuit, a formula to fall asleep; arnitrosium for joint pain; castor equi boiron ointment for treatment of cracked skin; and storinyl, a syrup to treat colds. further, it offers herbal medicines, such as canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of covid self-tests and rapid antigenic tests. the company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. boiron sa was founded in 1932 and is headquartered in messimy, france.

earnings per share

as for profitability, boiron has a trailing twelve months eps of €2.89.

pe ratio

boiron has a trailing twelve months price to earnings ratio of 13.67. meaning, the purchaser of the share is investing €13.67 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.13%.

volume

today's last reported volume for boiron is 5019 which is 31.14% below its average volume of 7289.

moving average

boiron's worth is below its 50-day moving average of €41.22 and way under its 200-day moving average of €44.80.

yearly top and bottom value

boiron's stock is valued at €39.50 at 22:10 est, way under its 52-week high of €53.20 and higher than its 52-week low of €38.20.

more news about boiron.

3. home invest be. (homi.br)

30.83% payout ratio

home invest belgium s.a. operates as a real estate investment company in belgium. it primarily invests in residential properties. as of december 31, 2008, the company's real estate portfolio consisted of 992 rental units with a total rentable space of approximately 111,091 square meters. the company was formerly known as home invest and changed its name to home invest belgium s.a. in may 1999. home invest belgium s.a. was founded in 1980 and is based in brussels, belgium.

earnings per share

as for profitability, home invest be. has a trailing twelve months eps of €3.22.

pe ratio

home invest be. has a trailing twelve months price to earnings ratio of 6.17. meaning, the purchaser of the share is investing €6.17 for every euro of annual earnings.

more news about home invest be..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com